Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUniversidade Estadual de Campinaspt
dc.typeArtigo de periódicopt
dc.titleMetformin Increases HDL3-Cholesterol and Decreases Subcutaneous Truncal Fat in Nondiabetic Patients with HIV-Associated Lipodystrophypt
dc.contributor.authorDiehl, LApt
dc.contributor.authorFabris, BApt
dc.contributor.authorBarbosa, DSpt
dc.contributor.authorDe Faria, ECpt
dc.contributor.authorWiechmann, SLpt
dc.contributor.authorCarrilho, AJFpt
unicamp.authorDiehl, Leandro A. State Univ Londrina UEL, CCS, Dept Clin Med, BR-86038350 Londrina, PR, Brazilpt
unicamp.authorDe Faria, Eliana C. State Univ Campinas UNICAMP, Campinas, SP, Brazilpt
dc.subject.wosLecithin-cholesterol Acyltransferasept
dc.subject.wosVirus-infected Patientspt
dc.subject.wosCardiovascular Riskpt
dc.subject.wosHdl Subpopulationspt
dc.description.abstractThe purpose of this study was to assess metformin effects on high-density lipoprotein (HDL) composition of patients with HIV-associated lipodystrophy (LDHIV). Twenty-four adult outpatients were enrolled to receive metformin ( 1700 mg/d) during 6 months, but 2 were lost to follow-up and 6 stopped the drug due to adverse events ( gastrointestinal in 5, and excessive weight loss in 1). From the 16 subjects who completed the study, 69% were female. At baseline, 3 and 6 months, we assessed: weight, waist and hip circumferences, blood pressure, fasting glucose and insulin, homeostasis model assessment of insulin resistance (HOMA2-IR), lipids, and HDL subfractions by microultracentrifugation. At 0 and 6 months, body fat distribution was assessed by computed tomography (CT) scan (L4 and middle femur). Metformin use was associated with reduction of mean weight (-2.4Kg at 6 months; p < 0.001), body mass index, waist, waist-to-hip ratio and a marked decrease in blood pressure (p < 0.001). Subcutaneous ( p = 0.01) and total abdominal fat (p = 0.002) were reduced, but no change was found in visceral or thigh fat. No difference was detected on plasma glucose, insulin, HOMA2-IR, cholesterol or triglycerides, except for an increase in HDL3-cholesterol (from 21 mg/dL to 24 mg/dL, p = 0.002) and a reduction of nascent HDL ( the fraction of plasma HDL-cholesterol not associated to subfractions HDL2 or HDL3) (p = 0.008). Adverse effects were very common, but most were gastrointestinal and mild. Thus, metformin use in LDHIV increases HDL3-cholesterol ( probably due to improved maturation of HDL) and decreases blood pressure, weight, waist, and subcutaneous truncal fat, making this an attractive option for preventing cardiovascular disease in this
dc.relation.ispartofAids Patient Care And Stdspt_BR
dc.relation.ispartofabbreviationAids Patient Care STDSpt
dc.publisher.cityNew Rochellept
dc.publisherMary Ann Liebert Incpt
dc.identifier.citationAids Patient Care And Stds. Mary Ann Liebert Inc, v. 22, n. 10, n. 779, n. 786,
dc.sourceWeb of Sciencept
dc.description.provenanceMade available in DSpace on 2014-11-20T04:39:38Z (GMT). No. of bitstreams: 1 WOS000260574000003.pdf: 354027 bytes, checksum: 3c7027fd61f7ff379873b3292e17d9fa (MD5) Previous issue date: 2008en
dc.description.provenanceMade available in DSpace on 2015-11-26T16:05:49Z (GMT). No. of bitstreams: 2 WOS000260574000003.pdf: 354027 bytes, checksum: 3c7027fd61f7ff379873b3292e17d9fa (MD5) WOS000260574000003.pdf.txt: 39741 bytes, checksum: ea74fc6f5581d344a953a5f79a91ad11 (MD5) Previous issue date: 2008en
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000260574000003.pdf345.73 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.